Alliancebernstein L.P. reduced its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 13.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 116,911 shares of the biopharmaceutical company’s stock after selling 18,400 shares during the period. Alliancebernstein L.P.’s holdings in Celldex Therapeutics were worth $422,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Norges Bank bought a new position in shares of Celldex Therapeutics during the fourth quarter worth about $1,248,000. Russell Investments Group Ltd. bought a new position in shares of Celldex Therapeutics during the fourth quarter worth about $325,000. Bank of New York Mellon Corp raised its position in shares of Celldex Therapeutics by 1.1% in the first quarter. Bank of New York Mellon Corp now owns 538,156 shares of the biopharmaceutical company’s stock worth $1,943,000 after buying an additional 5,616 shares in the last quarter. State of Wisconsin Investment Board raised its position in shares of Celldex Therapeutics by 206.3% in the first quarter. State of Wisconsin Investment Board now owns 750,000 shares of the biopharmaceutical company’s stock worth $2,708,000 after buying an additional 505,138 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its position in shares of Celldex Therapeutics by 26.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 6,000 shares in the last quarter. Hedge funds and other institutional investors own 65.83% of the company’s stock.
Celldex Therapeutics, Inc. (CLDX) traded up 1.65% during trading on Friday, hitting $2.47. 138,946 shares of the stock traded hands. The firm’s 50-day moving average is $2.47 and its 200 day moving average is $3.01. The stock’s market cap is $309.01 million. Celldex Therapeutics, Inc. has a 52 week low of $2.20 and a 52 week high of $5.02.
Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.05. The firm had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The business’s quarterly revenue was up 175.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.32) EPS. Equities research analysts forecast that Celldex Therapeutics, Inc. will post ($1.05) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2017/08/11/celldex-therapeutics-inc-nasdaqcldx-position-cut-by-alliancebernstein-l-p.html.
CLDX has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Tuesday, July 11th. Cowen and Company reiterated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, June 6th. HC Wainwright set a $10.00 target price on shares of Celldex Therapeutics and gave the company a “buy” rating in a research report on Wednesday. ValuEngine lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 3rd. Finally, BidaskClub lowered shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $7.32.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).
What are top analysts saying about Celldex Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celldex Therapeutics Inc. and related companies.